ABSTRACT: A boundary lubricant attaches and protects sliding bearing surfaces by preventing interlocking asperity-asperity contact. Proteoglycan-4 (PRG4) is a boundary lubricant found in the synovial fluid that provides chondroprotection to articular surfaces. Inflammation of the diarthrodial joint modulates local PRG4 concentration. Thus, we measured the effects of inflammation, with Interleukin-1a (IL-1a) incubation, upon boundary lubrication and PRG4 expression in bovine cartilage explants. We further aimed to determine whether the addition of exogenous human recombinant PRG4 (rhPRG4) could mitigate the effects of inflammation on boundary lubrication and PRG4 expression in vitro. Cartilage explants, following a 7 day incubation with IL-1a, were tested in a disc-on-disc configuration using either rhPRG4 or saline (PBS control) as a lubricant. Following mechanical testing, explants were studied immunohistochemically or underwent RNA extraction for real-time polymerase chain reaction (RT-PCR). We found that static coefficient of friction (COF) significantly decreased to 0.14 AE 0.065 from 0.21 AE 0.059 (p ¼ 0.014) in IL-1a stimulated explants lubricated with rhPRG4, as compared to PBS. PRG4 expression was significantly up regulated from 30.8 AE 19 copies in control explants lubricated with PBS to 3330 AE 1760 copies in control explants lubricated with rhPRG4 (p < 0.001). Explants stimulated with IL-1a displayed no increase in PRG4 expression upon lubrication with rhPRG4, but with PBS as the lubricant, IL-1a stimulation significantly increased PRG4 expression compared to the control condition from 30.8 AE 19 copies to 401 AE 340 copies (p ¼ 0.015). Overall, these data suggest that exogenous rhPRG4 may provide a therapeutic option for reducing friction in transient inflammatory conditions and increasing PRG4 expression. ß
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Treatment includes symptomatic relief using nonsteroidal anti-inflammatory drugs (NSAIDs), viscosupplementation, and ultimately arthroplasty. Joint replacement surgery led to $28.5 billion of hospitalization expenditures in 2009 in the United States 2 and comprised 35% of total arthritis-related procedures requiring hospitalization. 3 Post-traumatic osteoarthritis (PTOA) encompasses 12% of the OA case burden, 4 and is suspected to involve mechanical, biological, and environmental causes which together initiate and exacerbate cartilage degeneration. 5 Inflammation following joint trauma creates a nidus for the development of PTOA. 6 Interleukin-1 (IL-1) is one among many cytokines involved in joint inflammation. 7 The importance of IL-1 in the initiation and progression of OA is reflected by the clinical interest of insoluble IL-1 antagonists. 8 Proteoglycan-4 (PRG4), also referred to as lubricin, is a large, mucinous glycoprotein that coats the articular surfaces and provides articular cartilage boundary lubrication during high load and slow sliding speeds. 9 IL-1a and inflammation in general modulate PRG4 expression by synoviocytes as well as superficial and intermediate zone chondrocytes. 10 The N-terminus of PRG4 creates a disulfide bond between PRG4 monomers, enabling PRG4 to form a multilayer molecular film along the articular surface. 11 Hydration forces provided by O-linked mucin domain glycosylations are also likely involved in repulsion of molecules, since removal of distal NeuAc (sialic acid) and penultimate Gal (galactose) decreases lubricating ability in vitro. 12 Under conditions of reciprocating cyclic motion, boundary lubricants must be replenished to prevent articular wear. 13 Recently a link between elevated coefficient of friction (COF), increased mechanical strain, and increased chondrocyte caspase-3 activation in the absence of inflammation has been established both in vitro and in vivo in animal models lacking normal PRG4 lubrication. 13, 14 These observations coupled with the well-known catabolic effects resulting from mechanical injuries due to inflammatory mediators, such as IL-1, have initiated new inquiry into the anabolic role that PRG4 plays in the protection of articular chondrocytes. 15, 16 Downstream catabolic effects of IL-1 include stimulation of matrix metalloproteinase (MMP) production, increased proteoglycan release, and increased cartilage matrix degradation, which may initiate the phenomenon of PTOA. 17 These same metabolic dyscrasias are also accompanied by synovitis in OA. 18 Overexpression of IL-1b in rabbits results in cellular hyperplasia, articular cartilage loss, and clinical synovitis. 19 Isolated bovine and rat chondrocytes treated with IL-1a showed decreased PRG4 secretion and decreased PRG4 expression. 20, 21 IL-1b has also been shown to down-regulate PRG4 expression in chondrocytes. [20] [21] [22] However, other studies suggest that inflammation increases PRG4 production. [23] [24] [25] Whether exogenous PRG4 can attenuate the impact of IL-1 stimulation on native PRG4 expression by cartilage has not yet been reported.
PRG4 supplementation has been shown to improve the diminished lubricating ability of osteoarthritic, human synovial fluid. 26 In rodent PTOA models, following either meniscectomy 27 or anterior-cruciate ligament transection (ACLT), [28] [29] [30] the intra-articular dosing of PRG4 has demonstrated improved histology, [27] [28] [29] [30] increased cartilage thickness, 30 and preservation of glycosaminoglycan compared to untreated controls. 28, 29 Rats under forced exercise, in particular, showed greater damage without PRG4 supplementation following ACLT. 29 Additionally, Teeple et al. showed some radiographic improvement following PRG4 supplementation in post-ACLT rat knees. 30 Either recombinant human PRG4 (rhPRG4) or purified human synovial fluid PRG4 was used in the aforementioned studies. The half-life of rhPRG4 is short, following intra-articular PRG4 administration. 31 Thus, chondroprotective effects likely involve native expression of PRG4 to support these observations. 7, 29, 31, 32 We aimed to determine the effects of IL-1a on boundary lubrication and its biological impact on PRG4 expression in a cartilage-on-cartilage bovine explant model. 14 We posited that the posterior area of the femoral condyle, with less extractable PRG4, would be more susceptible to increases in friction due to IL-1a stimulation. 33 We further aimed to determine whether the addition of exogenous rhPRG4 could mitigate the effects of inflammation on boundary lubrication and PRG4 expression in vitro. We hypothesized that IL-1a stimulation of articular cartilage explants will induce cartilage catabolism, leading to a decrease in PRG4 expression and an increase in COF. Furthermore, we hypothesized that the introduction of rhPRG4, as a boundary lubricant, will have a restorative effect on cartilage through increasing chondrocyte native PRG4 expression and decreasing COF in IL-1a treated explants.
MATERIALS AND METHODS

Explant Harvest and Culture
Osteochondral explant pairs, 6 and 12 mm in diameter, were cored from bovine femoral condyles within 4 h of slaughter. Explants intended for both friction and immunohistochemical staining were acquired from 99 explants (79 mechanically stimulated, 20 controls) collected from 20 bovine femoral condyles from 20 adult steers between the ages of 12-16 months. Cartilage surfaces that appeared grossly deformed or damaged were rejected. Explant pairs were harvested from the anterior, mid, and posterior regions of the medial femoral condyle (Fig. 1) . A separate group of explants consisting of 12 explants harvested from three bovine femoral condyles from three donors was used for PRG4 expression evaluation. Another group of explants, consisting of twenty 12 mm explants and ten 6 mm and 12 mm explant pairs, was harvested from five bovine femoral condyles from five donors and used for dual imaging of native PRG4 and exogenous rhPRG4. All osteochondral explant groups were harvested from the medial region of the femoral condyle. Explant pairs underwent three washes with 5 ml of Dulbeccos Modified Eagles Medium containing 4.5g/L D-glucose and L-glutamine (DMEM) from (Gibco by Life Technologies, Carlsbad, CA) and centrifugation at 2,500 rpm for 5 min. Explants were then cultured for 7 days in the same DMEM containing 10% fetal bovine serum (Hyclone GE Life Sciences) and 1% penicillin streptomycin containing 5,000 U/ml penicillin and 5,000 mg/ml streptomycin (Gibco by Life 
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Technologies) 14 either with or without recombinant IL-1a at a concentration of 10 ng/ml in PBS (R&D Systems Inc., Minneapolis, MN). 14, 22 Medium containing IL-1a was changed at days 3 and 5 and new medium containing IL-1a was added.
Manufacture and Purification of rhPRG4
The expression of rhPRG4 by CHO-M cells has been described previously. 34 CHO-M cells were transfected with the full-length human PRG4 gene resulting in a full-length PRG4 (1,404 amino acids in length). The presence of O-linked glycosylations comprised of (b1,3) Gal-GalNAc was previously confirmed by mass spectrometry. 35 Mechanical Stimulation Methodology Explant pairs lubricated with 100 ml of either phosphatebuffered saline (PBS) or rhPRG4 (Lubris, LLC, Framingham, MA) from a stock solution of 1 mg/ml in PBS were mounted into a materials testing system (BOSE Electroforce 3200; Prairie Eden, MN). Mechanical stimulation of opposing explant pairs was preceded by 12 N static compression for 8 min, resulting in approximately 18% compressive strain. This interval allowed the pore pressure to depressurize within the cartilage samples to approximate toward zero. After depressurization, the explant pairs underwent 12 cycles of AE 720˚rotation while under constant axial strain. Static COF, a measure of the stick-slip condition, and dynamic COF (equilibrium COF) were calculated from the torque and axial load measured during the rotation sequence. The following equations were used:
where T max ¼ torque max within the first 20˚of rotation, T avg ¼ torque average for the last 720˚of rotation, R ¼ radius of the 6 mm explant, and F eq ¼ equilibrium force obtained after cartilage decompression.
14 Digital calipers were used to measure the initial total cartilage thickness values of the 12 mm and 6 mm explant bearing pairs. Four caliper values were measured and averaged for each explant in the pair and the total cartilage thickness was determined as the sum of the averaged explant thickness values forming the explant pair. Total cartilage thickness values were 1.48 AE 0.398 mm for the 6 mm explants, 1.28 AE 0.274 mm for the 12 mm explants, and 2.76 AE 0.609 mm for total cartilage thickness of all explant pairs. The total cartilage thickness of an explant pair was compared to the change in measured displacement across these two cartilage surfaces after mechanical loading had occurred. This comparison yielded a change in cartilage thickness for each of the explant pairs. Explant pairs with apparent compressive strains of 10% or less, or 30% or more were excluded. Secondly, if the standard deviation for the equilibrium force (F eq ) within explant pairs harvested from the same knee joint was 0.5 or greater, explant pairs whose F eq were less than 2 N, were excluded. These two criteria were used to minimize the impact of outliers on variability in COF, attributable in our experience, to abnormal specimen variability, inadequate mounting, and confounders caused by geometry of two surfaces that are not normally apposed or parallel to one another. Of the 79 explant pairs mechanically tested, 17 were excluded. Nominal F eq for the accepted explants was 2.84 AE 0.622 N. Data points used for the COF statistical analysis within each mechanical testing subset from the anterior, mid, and posterior region, respectively for the 79 explants taken from 20 bovine femoral condyles are as follows:
Histology Preparation
After COF measurement, the 12 mm explants from each testing pair were placed in formalin, decalcified with EDTA, and sectioned into 10 mm thick sections. PRG4 accumulation was determined from 62 explant pairs. PRG4 accumulation was visualized in these samples and the 20 non-mechanically stimulated 12 mm explant controls. Monoclonal antibody 9G3 (EMD Millipore; Darmstadt, Germany), which reacts with an epitope in the mucin domain of PRG4, was used to visualize PRG4 accumulation. 36 Control explants for each treatment group were immediately placed in formalin after 7 days of culture and not exposed to lubricant supplementation or mechanical stimulation.
Real-Time Polymerase Chain Reaction (RT-PCR)
The second group of 12 explants from three donors was cultured with or without 10 ng/ml of IL-1a for 7 days. Each of four explant pairs harvested from each bovine femoral condyle was assigned a different experimental group (either IL-PBS, IL-rhPRG4, Control-PBS, or Control-rhPRG4). Immediately after testing, the cartilage section of the osteochondral explant was separated from the bone. Cartilage samples were placed in an RNA preservation solution (RNAlater, Thermo Scientific) and stored at À80˚C until RNA isolation was performed. Three RNA samples were obtained for each of the four explant test groups. These three RNA samples were then pooled and evaluated in triplicate by RT-PCR.
Cartilage was minced with a #15 scalpel blade for RNA extraction. The RNA storage solution was carefully removed, and cartilage pieces were moved into 2 ml lysing matrix tubes (MP Biomedical, Santa Ana, CA) to which 700 ml QIAzol lysis buffer (QIAGEN, GmbH,D Hilden, Germany) was pipetted. The cartilage specimens were homogenized 10 times for 15 s, with 2 min of rest in ice between subsequent 15 s homogenization cycles (MP FastPrep-24 homogenizer MP Biomedicals, LLC. Santa Ana, CA). Total RNA was extracted and purified using miRNeasy micro kit (QIAGEN, GmbH,D Hilden, Germany) according to the manufacturer's protocol. The concentration of eluted RNA was determined via NanoDrop software3 (Thermo Scientific, Waltham, MA). cDNA was synthesized from 5 mg of total RNA. RT-PCR performed on a Mastercycler Realplex4 (Eppendorf, Hauppauge, NY) system using qPCR Kit Kapa Sybr fast master mix (Kapabiosystems, Boston, MA) and under conditions recommended by these manufacturers. After agarose gel analysis and purification of a 135 bp PCR product (QIAquick gel extraction kit.Qiagen Sciences, Germantown, MD), the DNA concentration was measured and a standard curve was created based on dilution. The same was also accomplished for glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Primer sequences for bovine PRG4 are as follows: Forward: 5-ACTCCACCACCTCCACCTCGG-3, Reverse: 5-GCTGAACG CTGCCACCTCTC-3. GAPDH was used as the internal The expression levels (number of copies) were normalized to GAPDH levels. PRG4 copy number was obtained from a standard curve with 100% efficiency. Sample copy number was expressed as number of copies of PRG4 per 100 copies of GAPDH.
Dual Imaging of rhPRG4 and Native PRG4 The third group of explants, described above, was harvested for PRG4 dual imaging of rhPRG4 and resident bovine PRG4. This group of explants consisted of twenty 12 mm explants that were not mechanically stimulated and ten 6 and 12 mm explant pairs that were mechanically stimulated. These explants were harvested from five bovine femoral condyles from five donors and cultured with or without 10 ng/ml of IL-1a for 7 days. Each of the four 12 mm explants and two 6 and 12 mm explant pairs harvested from each bovine femoral condyle were assigned to a different nonmechanical (IL-rhPRG4, IL, Control-rhPRG4, or Control) or mechanical (IL-rhPRG4 or Control-rhPRG4) testing group. rhPRG4 was labeled using a Pierce NHS-rhodamine antibody labeling kit (Thermo Fisher Scientific; Grand Island, NY) according to manufacturer instructions using a 2 mg/ml concentration of rhPRG4. Explants were then exposed to 100 ml of PBS or rhPRG4-rhodamine as a lubricant for 15 min with and without mechanical stimulation using the mechanical stimulation protocol described above. Cartilage was removed from bone immediately after experimentation and frozen at À80˚C. Sections of frozen cartilage were then cut and stained with 9G3 and DAPI before being imaged. Two sections of cartilage were stained and imaged per sample with five samples evaluated per test group.
Statistical Analysis
Three-way analyses of variance (ANOVA) were used to determine the effects of lubricant (PBS vs. rhPRG4), IL-1a incubation condition (IL-1a treated vs. control), and cartilage harvest region (anterior, mid, and posterior) on static and dynamic COF values in mechanically stimulated bovine cartilage explants. Lubricant and IL-1a incubation condition were across-subject factors and harvest region was a withinsubject factor in the model. If significant interactions were detected, partial F-tests were used post hoc to test simple effects (e.g., lubricant effect within IL-1a incubation condition or IL-1a effect within lubricant). Similarly, a two-way ANOVA followed by partial F-tests were used to determine the effects of the lubricant and IL-1a incubation condition on PRG4 expression assayed via RT-PCR. Because RT-PCR data was log transformed prior to analysis, geometric means, and their associated standard errors are presented. All analyses were performed using SAS Version 9.4 (SAS Institute, Cary, NC). Statistical significance determined based on p < 0.05.
RESULTS
Application of rhPRG4 to Cartilage Explants Stimulated With IL-1 Restores Low Friction PRG4 accumulation at the articular surface (Fig. 2) was qualitatively diminished in IL-1a treated, nonmechanically stimulated explants (IL) compared to their IL-1a free, non-mechanically stimulated counterparts (Control). The lack of PRG4 accumulation at the articular surface of IL-1a stimulated explants was restored upon lubrication with rhPRG4 but diminished upon lubrication with PBS (Fig. 2) . These qualitative observations in PRG4 surface accumulation parallel the static COF data in Figure 3A , where explants with decreased PRG4 available at the articular surface demonstrated higher static COF. Three-way analysis of variance results indicate that the effect of lubricant on static COF values was dependent upon whether or not IL-1a was present (lubricant by IL-1a condition interaction, p ¼ 0.022). IL-1a treated explants lubricated with PBS during mechanical stimulation displayed significantly higher static COF values compared to IL-1a free explants lubricated with PBS (p ¼ 0.02). No significant difference was observed between IL-1a conditions in rhPRG4 lubricated explants (p ¼ 0.37). Additionally, IL-1a treated, Figure 2 . PRG4 Immunohistochemistry. Immunohistological detection of PRG4 by 9g3 (green) and cell nuclei via DAPI (blue) in nonmechanically stimulated (ÀMechanical) and mechanically stimulated (þMechanical) bovine cartilage explants cultured with IL-1a (þIL-1a, IL) or IL-1a free media (-IL-1a, Control) is shown in six representative images. Either phosphate buffered saline (PBS) or recombinant PRG4 (rhPRG4) was used as a lubricant for mechanically stimulated explants. IL-1a treated, nonmechanically stimulated explants (n ¼ 20) displayed decreased PRG4 compared to control treated, non-mechanically stimulated explants (Control, n ¼ 20). IL-PBS explants (n ¼ 13) displayed no change in PRG4 while IL-rhPRG4 explants (n ¼ 16) displayed increased PRG4 on the surface comparable to Control explants and Control-rhPRG4 explants (n ¼ 19). Control-PBS explants (n ¼ 14) displayed marked decrease in PRG4 compared to Control and Control-rhPRG4 explants. Scale bar is 50 m.
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rhPRG4 lubricated explants displayed significantly lower static COF compared to IL-1a treated, PBS lubricated explants (p ¼ 0.014). The significantly lower mean static COF (0.14 AE 0.065) for IL-1a treated, rhPRG4 lubricated explants compared to the mean static COF (0.21 AE 0.059) for IL-1a treated, PBS lubricated explants indicates that rhPRG4 has the ability to increase boundary lubrication in IL-1a treated explants. Mean static COF (0.16 AE 0.066) of IL-1a free explants lubricated with rhPRG4 and the static COF (0.15 AE 0.052) for IL-1a free explants lubricated with PBS were not significantly different (p ¼ 0.44). Thus, residual PRG4 at the articular surface of IL-1a free explants was capable of compensating for the lack of lubrication provided by PBS and may account for the lack of significant difference in friction values for IL-1a free explants lubricated with rhPRG4 compared to lubrication with PBS (Fig. 2) .
When dynamic COF was examined, analyses of variance results indicated no significant effect of Static and dynamic COF values separated by location from the anterior, mid, and posterior regions of the femoral condyle are displayed in Figure 3B . Based on three-way analyses of variance results, there was no evidence that static or dynamic COFs differed across regions (p ¼ 0.26 and p ¼ 0.59, respectively), nor was there evidence that the effects of lubricant and/or IL-1a incubation condition were region dependent (all interactions, p's > 0.10).
Labeled rhPRG4 Accumulates on the Articular Surface Rhodamine labeled rhPRG4 was used to assess the extent to which rhPRG4 attached and infiltrated the cartilage in IL-1a stimulated explants lubricated with rhPRG4 and IL-1a free explants lubricated with rhPRG4. A greater amount of rhodamine labeled rhPRG4 was observed in the cartilage of IL-1a stimulated explants compared to IL-1a free controls (Fig. 4) . It appeared that rhPRG4 markedly accumulated on the cartilage surface.
Restoration of PRG4 Expression via rhPRG4 in IL-1a Stimulated Cartilage Explants
Based on the two-way analysis of variance, there was a significant interaction between lubricant and IL-1a incubation condition on PRG4 expression (p ¼ 0.006). PRG4 expression was significantly up regulated from 30.8 AE 19 copies in IL-1a free explants lubricated with PBS to 3,330 AE 1,760 copies in IL-1a free explants lubricated with rhPRG4 (p < 0.001) (Fig. 5) . These data indicate that rhPRG4 significantly increases native PRG4 expression in cartilage explants undergoing mechanical stimulation when not exposed to inflammation. Explants stimulated with IL-1a did not respond in this manner. There was a significant increase in PRG4 expression from 30.8 AE 19 copies in IL-1a free explants lubricated with PBS to 401 AE 340 copies in IL-1a stimulated explants lubricated with PBS (p ¼ 0.015). Conversely, explants stimulated with IL-1a and lubricated with rhPRG4 trended toward significantly decreased PRG4 expression from 3,330 AE 1,760 copies in IL-1a free explants lubricated with rhPRG4 to 525 AE 41.2 copies (p ¼ 0.057).
DISCUSSION
This study indicated that IL-1a stimulation of bovine cartilage explants resulted in significantly increased static COF under lubrication with PBS and that rhPRG4 was capable of significantly lowering increased COF under this inflammatory condition in vitro. Furthermore, we showed that in the IL-1a free condition PRG4 expression is significantly up regulated with use of rhPRG4 as a lubricant and that the effect of IL-1a stimulation on PRG4 expression compared to the IL-1a free condition is lubricant dependent under mechanical stimulation. However, we did not observe the same findings upon analyzing explants separately from the anterior, mid, and posterior regions of the femoral condyle. This is perhaps due to small regional sample size numbers, especially in the posterior region, which partly occurred as a result of our exclusion criteria. This observation must be reconciled with other studies that showed explants from the anterior femoral condyle contained greater extractable amounts of PRG4 compared to explants from the posterior area. 33, 37 Recently, Peng et al. found significant differences in equilibrium COF between the anterior-most and posterior-most cartilage regions of the femoral condyle in a pin-on-disc tribological system with cartilage harvested from calves. 37 Our present study evaluated static and dynamic COF in the anterior, mid, and posterior regions of the femoral condyle using a cartilage-on-cartilage set up with explants harvested from skeletally mature adult steers. Peng et al. Figure 4 . Immunohistochemistry of PRG4 in the presence of exogenous rhodamine labeled rhPRG4. Representative images showing exogenous rhPRG4 (red) and a combination of exogenous and endogenous PRG4 for IL-1a treated (þIL-1a) and control (-IL-1a) explants with (þrhPRG4) or without (-rhPRG4) rhodamine labeled rhPRG4. Green indicates detection of all PRG4 present by 9g3 (whether endogenous or exogenous) and red indicates exogenous, rhodamine-labeled rhPRG4. Counter staining of cell nuclei with DAPI is blue. Samples lubricated with rhPRG4 were either mechanically stimulated (þMechanical) or not mechanically stimulated (ÀMechanical). IL-1a stimulated explants without rhPRG4 (n ¼ 5) exhibited little to no endogenous PRG4, while IL-1a stimulated samples with rhPRG4 (n ¼ 5) displayed greater amounts of exogenous rhPRG4 penetrating into the cartilage superficial zone. IL-1a stimulated samples appear to exhibit more exogenous rhPRG4 attachment than their IL-1a free counterparts (n ¼ 5). This suggests that IL-1a stimulation diminishes endogenous PRG4 while allowing for increased exogenous rhPRG4 attachment and penetration into the cartilage tissue. Scale bar is 100 m.
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only allowed for 2 min of cartilage depressurization following a 0.1 MPa load and performed studies at a 0.5 mm/s sliding speed, which is faster than commonly used in other tribological studies. [38] [39] [40] [41] Our present work used 8 min of depressurization following a 0.42 MPa load and a 0.3 mm/s sliding speed coupled with rigorous exclusion criteria.
Immunohistochemistry confirmed that rhodaminelabeled rhPRG4 attached to the cartilage surface, possibly infiltrated the superficial zone, and provided a surface coating that recapitulates native PRG4, particularly in the IL-1a stimulated explants. This rhPRG4 coating acted as an anti-adhesive and lubricating physisorbed layer that diminished both static and dynamic friction in IL-1a stimulated, bovine cartilage explants. These in vitro inflamed explants showed little to no residual, native PRG4 at the cartilage surface. Thus, the significant reduction in dynamic and static friction between IL-1a stimulated explants lubricated with saline compared to IL-1a stimulated explants lubricated with rhPRG4 was due to the restoration of boundary lubrication by the addition of exogenous rhPRG4. Also, the lack of a statistically significant difference in friction between IL-1a stimulated explants lubricated with rhPRG4 and IL-1a free explants lubricated with saline indicates that rhPRG4 may be lubricating just as effectively as the naturally expressed residual bovine PRG4 found on IL-1a free explants. The exact mechanism by which IL-1a removes PRG4 from the surface has yet to be fully determined. However, we posit that the combination of PRG4 down regulation by IL-1a, along with increased MMP production in IL-1a exposed cartilage, 17 promotes the removal of PRG4 from the cartilage surface.
Our current work indicates that exogenous rhPRG4 and, thus perhaps, synovial PRG4 have mechanobiological effects. The articular surface of IL-1a free cartilage re-lubricated by rhPRG4 resulted in more native PRG4 expression. The mechanism through which rhPRG4 up regulates native PRG4 expression has yet to be fully elucidated. However, prior reports describe that the combination of load and lubricated mechanical sliding increases PRG4 expression. 42, 43 The up regulation of PRG4 expression in IL-1a stimulated explants evidently depends upon the lubricant used. PBS as the lubricant led to an increase in PRG4 expression, whereas rhPRG4 as the lubricant may have led to a decrease in PRG4 expression. Overall, the IL-1a stimulation appeared to interfere with the normal mechanobiological response of cartilage to the combination of load and lubricated mechanical sliding. These results also support PRG4's role as the primary boundary lubricant in synovial fluid since neither HA nor surface-active phospholipids were added. Overall, HA may play a synergistic role with PRG4 in lowering COF, 39 but the role phospholipids play in boundary lubrication is unclear. [44] [45] [46] [47] In regards to whether or not PRG4 has a direct anti-inflammatory effect, a recent study showed that PRG4 competes with HA in binding CD44, and initiating an antiinflammatory response. 48 Intra-articular delivery of rhPRG4 may be therapeutically applicable to other forms of joint inflammation as well. Indeed, human synovial fluid samples from patients with OA and RA patients, 49 as well as menisci from OA patients, 50 have been shown to contain decreased PRG4 compared to control samples. In other work, human RA tissue samples from patients with advanced disease progression displayed significantly decreased PRG4 expression compared to control samples. 51 Prior studies indicate that PRG4 protein levels are decreased with inflammation, 20, 52, 53 and that PRG4 mRNA expression is down regulated. 21, 22, 54 However, PRG4 levels were increased at certain time-points in models of PTOA. [23] [24] [25] Quantification of PRG4 using ELISA and Western blot carry the limitations inherent in the anti-PRG4 antibodies currently available. These antibodies detect either a terminal end of the PRG4 protein or the glycosylated mucin domain. 36 Thus, PRG4 protein fragments, generated by increased proteolytic activity in inflammatory conditions, may have been detected and reported in lieu of intact PRG4 protein in these previous studies.
Limitations of this study include that bovine cartilage samples were obtained from specimens of varying ages and only from the medial femoral condyles of the animals. We had greater consistency in harvesting from a curved surface like the femoral condyle but this also creates the limitation of not having a paired tibial plateau cartilage surface. Only 8 min for cartilage depressurization was allowed in order to maintain cartilage viability during friction testing to enable subsequent immunohistology and RNA isolation. Eight minutes approximates a majority of the depressurization but is not maximal. 55 However, the equilibrium loads used in this study were similar to prior tribological studies. 56 Additionally, the cartilage explant bearings in this study were cultured to maintain cell viability and only mechanically stimulated once. This enabled us to determine the mechanical, cartilageon-cartilage, frictional effects as well as the biological effects of IL-1a stimulation on protein expression in chondrocytes for the 12 mm explant from each explant pair. A gimbal system 57, 58 was not in place in our test system to maintain perfect co-planarity as the two oscillating cartilage surfaces moved past one another during the friction tests. Thus, variations in friction caused by surface imperfections or imprecise mounting could also cause a sporadic increase in friction, which is why criteria were established for acceptability of the data.
CONCLUSIONS
Exogenous rhPRG4 significantly reduced static friction values for IL-1a stimulated, bovine cartilage explants. Immunohistochemistry for PRG4 showed removal of PRG4 from the cartilage surface during IL-1 stimulation. This PRG4 deficiency at the surface was restored upon addition of rhPRG4 as a lubricant. Additionally, IL-1a free cartilage explants showed significantly increased PRG4 expression when lubricated with rhPRG4 compared to saline. IL-1 alters the normal mechanobiological response of cartilage to the combination of load and lubricated mechanical sliding.
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